Podcast appearances and mentions of Anil K Sood

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Anil K. Sood to discuss novel high-grade serous ovarian morphologic classification. Dr. Sood is a Professor in the Department of Gynecologic Oncology and Reproductive Medicine at the UT MD Anderson Cancer Center. He is Co-Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and co-leads the Ovarian Cancer Moonshot Program. He is an elected member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), and the National Academy of Medicine (NAM). Highlights: - High grade serous ovarian cancer (HGSOC) could be classified into two gross morphologic subtypes. - Type I and type II morphologic subtypes differed with respect to clinical outcomes. - The two morphologic subtypes also differed with regard to transcriptomic, proteomic, and metabolomic profiles.

Hosted by: Anil K. Sood, MD, MD Anderson Cancer Center Featuring: Tilley Jenkins Vogel, MD, Northshore University HealthSystem Shannon N. Westin, MD, MPH, UT MD Anderson Cancer Center Editor's Choice Paper: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers Editorial: Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls

Hosted by: Anil K. Sood, MD, MD Anderson Cancer Center Featuring: Tilley Jenkins Vogel, MD, Northshore University HealthSystem Shannon N. Westin , MD, MPH, UT MD Anderson Cancer Center Editor's Choice Paper: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers Editorial: Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls

The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling. In the present study, the authors examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression in gynecologic cancer models. Murine orthotopic models of ovarian and uterine cancer were used to study the biological effects of L-Grb2 on tumor growth. In vitro experiments were carried out to elucidate the mechanisms and potential predictors of tumor response to L-Grb2. Treatment with L-Grb2 decreased tumor growth and metastasis in orthotopic models of ovarian cancer by reducing angiogenesis and increasing apoptosis at a dose of 15 mg/kg with no effect on mouse body weight. Reverse-phase protein array analysis identified significant dysregulation of metabolites in ovarian cancer cells after Grb2 downregulation. L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer. Dr. Anil K. Sood and Dr. Cristian Rodriguez-Aguayo from The University of Texas MD Anderson Cancer Center said, "Adaptor proteins are essential for signal propagation after receptor tyrosine kinase (RTK) activation." Druggable targets have often been proteins with enzymatically active sites to which small molecules could bind. However, the ability to target previously undruggable targets is evolving. Small-molecule inhibitors rely on intracellular targets or antibodies to inhibit the activity of growth factors, cell surface receptors, and cytokines. The development of nucleic acid interference-based therapeutics has allowed for regulation of gene expression to inhibit elusive targets. Nucleic acid-based therapeutics involves a process in which RNA molecules or antisense oligonucleotides inhibit gene expression or translation by neutralizing targeted mRNA molecules. After crossing the cell membrane, ASOs target mRNA directly through complementary base pair interactions, in the nucleus or cytosol, thus blocking and neutralizing targeted mRNAs. The Sood/Rodriguez-Aguayo Research Team concluded in their Oncotarget Research Paper, "we report that L-Grb2 has promising antitumor activity in preclinical models of ovarian and uterine carcinoma. Whereas the evidence of L-Grb2's activity against hematological malignancies is promising, whether it is active in clinical trials against solid tumors has yet to be tested. Therapies targeting the ErbB2 receptor have had limited success in ovarian cancer, but L-Grb2 may be a better target given its status as an important converging point for cancer cell signaling pathways." Sign up for free Altmetric alerts about this article DOI - https://doi.org/10.18632/oncotarget.27667 Full text - https://www.oncotarget.com/article/27667/text/ Correspondence to - Anil K. Sood - asood@mdanderson.org and Cristian Rodriguez-Aguayo - CRodriguez2@mdanderson.org Keywords - ovarian cancer, nucleic-acid based therapeutics, therapeutic approaches, uterine cancer About Oncotarget Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105

January 19, 2016 - Anil K. Sood, M.D., Professor, Vice Chair, Translational Research, Departments of Gynecologic Oncology and Cancer Biology, Co-Director, Center for RNAi and Non-Coding RNA, Director, Blanton-Davis Ovarian Cancer Research Program “About Stress, Nerves, and Cancer Metastasis” The Lecture Series was kindly underwritten by the Friends of Integrative Medicine, The Estate of Jerry J. Moore and the Center for Energy Balance

Anil K. Sood, MD, Professor, Gynecologic Oncology & Reproductive Medicine

Hosted by: Anil K. Sood, MD, MD Anderson Cancer Center Featuring: Tilley Jenkins Vogel, MD, Northshore University HealthSystem Shannon N. Westin , MD, MPH, UT MD Anderson Cancer Center Editor's Choice Paper: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers Editorial: Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls